From a garage venture to an industry bellwether: Biocon under Kiran Shaw

Karnataka aims to grow its bioeconomy to $100 billion by 2030, with a target CAGR of 19% to reach the goal.

Kiran Mazumdar-Shaw announced a phased, five-year succession plan naming her niece Claire Mazumdar as her successor. Claire is the 37-year-old founder and CEO of Bicara Therapeutics (Nasdaq-listed), incubated by Biocon; she is the daughter of Ravi Mazumdar and Catherine Rosenberg and holds degrees from MIT and Stanford, including a PhD in cancer biology.

Biocon reported a 63% year-on-year fall in fourth-quarter net profit to Rs 126 crore. The company noted growth in core businesses but incurred an Rs 80 crore exceptional charge for business integration and the impact of the new labour codes.

To strengthen leadership during the transition, Shreehas Tambe was appointed as CEO and Managing Director in April 2026.

Biocon announced it would integrate its generics and biosimilars into a unified global biopharma platform by March 31, 2026, consolidating Biocon Biologics into the parent company and sharpening focus on diabetes, oncology and immunology.

Karnataka's bioeconomy was valued at $39.2 billion as of March 2026, accounting for about 21% of India's total bioeconomy and contributing over 10% to the state's GDP. The sector grew 26.5% between 2023 and 2025 and adds nearly $10 billion to the economy each quarter.

From 2010 onwards, Biocon focused on biosimilars, oncology and advanced biologics.

Biocon expanded into biopharmaceuticals, insulin, statins and novel biologics during the 2000s.

In the late 1990s, banks were reluctant to lend to women entrepreneurs; Mazumdar-Shaw lobbied the Karnataka government and secured KIADB land to set up Biocon ventures, Biocon Park and healthcare infrastructure.

Kiran Mazumdar-Shaw launched Biocon in her Bengaluru garage with an initial capital of ₹10,000, in partnership with Ireland’s Biocon Biochemicals.